# Scholar Rock Holding Corp > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Scholar Rock Holding Corp). ## Overview Scholar Rock Holding Corp is a U.S.-based biotechnology company focused on discovering and developing medicines that modulate growth factor signaling for severe diseases. Its lead programs center on apitegromab and other anti-myostatin candidates for neuromuscular disorders, with development, manufacturing, and future commercialization activities organized through third-party partners and internal research capabilities. ## Products & services • Apitegromab, a therapeutic candidate for spinal muscular atrophy • Anti-myostatin pipeline programs for neuromuscular diseases • SRK-439 and other proprietary discovery-stage candidates • Antibody discovery and optimization using internal and third-party capabilities • Clinical development and regulatory advancement services for its pipeline - **Lead therapeutic candidate** (0%) — Apitegromab and related clinical-stage development for SMA and adjacent neuromuscular uses. - **Pipeline biologics** (0%) — Anti-myostatin and other antibody-based programs under preclinical and clinical development. - **Discovery platform** (0%) — Proprietary antibody discovery and optimization capabilities used to generate new candidates. - **Development and regulatory activities** (0%) — Clinical trial execution, regulatory filings, and supporting development work for product candidates. - Apitegromab, a therapeutic candidate for spinal muscular atrophy - Anti-myostatin pipeline programs for neuromuscular diseases - SRK-439 and other proprietary discovery-stage candidates - Antibody discovery and optimization using internal and third-party capabilities - Clinical development and regulatory advancement services for its pipeline ## Customers Scholar Rock’s direct end customers, if its products are approved, are patients with rare neuromuscular diseases and the physicians who treat them. In practice, commercialization depends on neurologists, specialty clinics, hospitals, and third-party payors that determine prescribing, access, and reimbursement. The company also relies on contract manufacturers, research vendors, and potential commercial partners to support development and launch activities. - **SMA patients and treating physicians** (primary) — They would use apitegromab if approved to treat spinal muscular atrophy and related neuromuscular conditions. - **Rare disease payors and market access stakeholders** (primary) — They determine coverage, reimbursement, and formulary access for high-cost specialty biologics. - **Specialty neuromuscular clinics** (secondary) — They diagnose, monitor, and administer therapies for patients in the target disease areas. - **Research and manufacturing partners** (secondary) — They provide discovery, clinical manufacturing, and development services under outsourced arrangements. - Patients with spinal muscular atrophy and other rare neuromuscular diseases - Neurologists and specialty physicians who prescribe advanced therapies - Hospitals and specialty clinics that administer treatment - Third-party payors that influence access and reimbursement - Contract manufacturers and research vendors supporting development ## Geography Scholar Rock is headquartered in the United States and develops therapies for global markets, with commercialization planning in both the U.S. and Europe. The company has specifically referenced launch preparation in Germany as part of its European build-out, while clinical and regulatory work spans U.S. and European agencies. Its outsourced manufacturing and development model also creates exposure to third-party suppliers and service providers across multiple jurisdictions. - Headquartered in the United States - Primary development and regulatory activity in the U.S. - European commercialization planning includes Germany - Global launch intent for approved products - Outsourced manufacturing and vendors add cross-border execution risk ## Strategy The company’s strategy is to advance apitegromab through regulatory approval and build the commercial infrastructure needed for launch in neuromuscular disease. It is also broadening its pipeline around anti-myostatin biology while relying on outsourced manufacturing and selective external partners to scale efficiently. - **Regulatory advancement of apitegromab** (short-term) — Approval is the key value-creation step and the basis for first product revenue. - **Commercial build-out** (short-term) — The company needs sales, market access, medical affairs, and distribution capabilities to launch. - **Pipeline expansion** (medium-term) — A broader portfolio reduces dependence on a single lead asset and extends the platform. - Advance apitegromab through U.S. and European regulatory pathways - Build commercial capabilities for rare-disease launch execution - Expand the anti-myostatin pipeline beyond the lead program - Use third-party manufacturers and vendors to support development - Protect intellectual property around its antibody platform ## Risks Scholar Rock faces the classic biotech risk stack: clinical failure, regulatory delay, and uncertainty around eventual commercialization. Because it has no product sales history and depends on third parties for manufacturing and development, execution risk, reimbursement risk, and financing needs are all material. - **Clinical development failure** [critical] — Lead assets must prove efficacy and safety in pivotal and follow-on studies before approval. - **Regulatory delay or rejection** [high] — FDA and EMA decisions determine whether the company can commercialize its lead product. - **Commercialization execution risk** [high] — The company has limited sales and distribution experience and must build capabilities or partner. - **Reimbursement and pricing pressure** [high] — Specialty biologics depend on third-party payor coverage and favorable access terms. - **Manufacturing and supply chain dependence** [medium] — All clinical manufacturing is outsourced, increasing reliance on third-party capacity and quality. - Clinical trials may fail to show sufficient efficacy or safety - Regulatory review can delay or block approval of apitegromab - Commercial launch depends on building sales and market access capabilities - Reimbursement and pricing pressure can limit uptake - Third-party manufacturing and vendors create supply and quality risk - The company may need additional capital before programs are fully commercialized ## Accounting The most important accounting issue is the company’s ongoing loss profile and the judgment involved in estimating future funding needs, clinical costs, and commercialization spend. Investors should also watch stock-based compensation, equity award modifications, and any future license, milestone, or collaboration accounting tied to development-stage biotech arrangements. - **Research and development expense recognition** — Affects operating loss and comparability across periods - **Stock-based compensation** — Can materially affect reported operating expense - **Capitalization and liquidity assumptions** — Important for going-concern and financing analysis - **Collaboration and license accounting** — Could affect revenue or other income recognition - No product revenue yet, so results are driven by R&D and G&A expense - Stock-based compensation and award modifications can materially affect G&A - Clinical trial and manufacturing costs are expensed as incurred - Future license, milestone, or collaboration terms may affect revenue timing - Going-concern and liquidity assumptions depend on future capital access --- *Last updated: 2026-04-29T04:57:41.070802+00:00*